Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the value of real-world data in the field of CAR T-cell therapies. Real-world data can provide much-added value and information compared with prospective data. Particularly in the CAR-T field, the multitude of different stakeholders requires additional, comprehensive information, including effectiveness in larger real-world populations. Therefore, real-world evidence can complement data from clinical trials to help inform clinicians, patients, regulatory agencies, and payers. Additionally, Prof. Mohty highlights how real-world data will help develop non only the CAR-T field but also cellular therapy in general. This interview took place during the 3rd European CAR T-cell Meeting.